赛升药业（300485）7月29日主力资金净流入3786.23万元

Group 1 - The core viewpoint of the news is that Sai Sheng Pharmaceutical has shown a mixed financial performance in the latest quarter, with a significant drop in revenue but a substantial increase in net profit [1] - As of July 29, 2025, the company's stock price closed at 15.55 yuan, reflecting a 4.43% increase, with a trading volume of 526,200 hands and a transaction amount of 808 million yuan [1] - The net inflow of main funds was 37.86 million yuan, accounting for 4.69% of the transaction amount, indicating a positive sentiment among investors despite the mixed financial results [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 92.54 million yuan, a year-on-year decrease of 15.52%, while the net profit attributable to shareholders was 39.97 million yuan, a year-on-year increase of 120.97% [1] - The company's current ratio was 23.584, the quick ratio was 22.421, and the debt-to-asset ratio was 4.58%, indicating strong liquidity and low leverage [1] - Sai Sheng Pharmaceutical has made investments in 14 companies and participated in 383 bidding projects, showcasing its active engagement in the industry [2]